Morgan Stanley analyst Craig Hettenbach raised the firm’s price target on Tenet Healthcare (THC) to $247 from $232 and keeps an Overweight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Hospital stocks lower after Republicans propose Medicare funding cut
- Tenet Healthcare price target raised to $257 from $238 at Guggenheim
- Tenet Healthcare Board Member Resigns, Board Size Reduced
- Tenet Healthcare price target raised to $240 from $229 at Barclays
- Tenet Healthcare Issues $2.25 Billion in New Notes